To view this email as a web page, click here.
 
FDA adds key label expansion to blockbuster anticoagulant
A new indication for the blockbuster Factor Xa inhibitor rivaroxaban (Xarelto) has been approved by FDA.
Read more
 
Biologic gets asthma indication
A novel treatment for patients with moderate-to-severe asthma is now on the market.
Read more
 
New migraine treatments offer options for patients
The migraine prevention drug market has suddenly heated up, with 2 new approvals by FDA.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.